| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692531 | The Breast | 2017 | 9 Pages |
Abstract
To our knowledge, this is the first cohort study showing systemic first-line therapy for all subtypes of advanced breast cancer. Overall survival in the TMK is comparable to that reported by clinical trials despite the inclusion of older and comorbid patients.
Keywords
MCRGEMLAPCTXCCIESMOeCRFNCCNHER2DFIVinorelbineBEVT-DM1EribulinABCtMKE/AEuropean Society for Medical Oncologyoverall survivalbevacizumabTrastuzumabRegistriesGemcitabinereal-world dataDocetaxelperEndocrine therapyTargeted therapyAdvanced breast cancerOutpatientsCharlson Comorbidity IndexNational Comprehensive Cancer NetworkVINChemotherapyconfidence intervalDisease-free intervalElectronic case report formLapatinibCARERIPalliative careCohort studiestraBreast neoplasmsPaclitaxelPertuzumabAGOCarboplatinCaPCapecitabineHuman epidermal growth factor receptor 2hormone receptor
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Thomas Fietz, Hans Tesch, Jacqueline Rauh, Emil Boller, Lisa Kruggel, Martina Jänicke, Norbert Marschner, the TMK-Group (Tumour Registry Breast Cancer) the TMK-Group (Tumour Registry Breast Cancer),